TriLink
Advertisement
Articles by TriLink
Increasing mRNA yields using CleanCap® M6 pulse-feed protocol. This technical note reviews the in vitro transcription (IVT) kinetics of CleanCap M6, including those associated with a supplementary pulse-feed protocol to increase IVT yields and help lower the costs associated with mRNA manufacturing.
mRNA vaccines and therapeutics continue to reshape medicine, providing unique opportunities to prevent and treat a wide range of diseases. In order to unleash the full potential of mRNA, however, one must consider various factors.
Want to increase the probability success for your discovery mRNA program? Partner with TriLink BioTechnologies®. Since 2012, we’ve been the industry leader in custom mRNA synthesis for research and clinical applications. Read on to see how TriLink® is determined to deliver you success.
Advertisement
Latest Updated Articles
- All Things mRNA: Strategies for Effective mRNA Vaccine and Therapeutic Development
Published: June 24th 2024 | Updated:
- Discovery mRNA manufacturing capabilities built with one thing in mind, your success
Published: January 15th 2024 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
4
Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization
5
